Media headlines about Marinus Pharmaceuticals (NASDAQ:MRNS) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.3882779858949 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities analysts have recently issued reports on the company. Laidlaw assumed coverage on Marinus Pharmaceuticals in a research report on Thursday, December 14th. They set a “buy” rating and a $18.00 price objective for the company. Mizuho assumed coverage on Marinus Pharmaceuticals in a research report on Monday, March 19th. They set a “buy” rating and a $13.00 price objective for the company. BidaskClub downgraded Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, HC Wainwright assumed coverage on Marinus Pharmaceuticals in a research report on Thursday, February 15th. They set a “buy” rating and a $33.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $18.75.
Shares of MRNS stock opened at $4.15 on Friday. Marinus Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $9.87.
In other Marinus Pharmaceuticals news, CEO Christopher Michael Cashman sold 9,566 shares of Marinus Pharmaceuticals stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $6.28, for a total value of $60,074.48. Following the completion of the sale, the chief executive officer now directly owns 247,903 shares in the company, valued at $1,556,830.84. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/06/marinus-pharmaceuticals-mrns-earning-somewhat-favorable-press-coverage-report-finds/2029800.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.